![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Antiviral activity of JNJ-4964 (AL-034/TQ-A3334),a selective Toll-Like Receptor 7 agonist, after oral administration for 12 weeks in AAV/HBV mice
|
|
|
Reported by Jules Levin
EASL 2019 April 10-14 Vienna
Florence Herschke1, Chris Li2, Ren Zhu2, Qinglin Han2, Qing Lu2, Erio Barale1, Sandra De Jonghe1, Tse-I Lin3,An De Creus1
1Janssen PharmaceuticaNV, Beerse, Belgium
2Janssen China R&D Center, Shanghai, China
3Formerly Janssen Biopharma (a Janssen Pharmaceuticals company), San Francisco, USA
![0418191](../images/041919/041919-4/0418191.gif)
![0418192](../images/041919/041919-4/0418192.gif)
![0418193](../images/041919/041919-4/0418193.gif)
![0418194](../images/041919/041919-4/0418194.gif)
![0418195](../images/041919/041919-4/0418195.gif)
![0418196](../images/041919/041919-4/0418196.gif)
![0418197](../images/041919/041919-4/0418197.gif)
![0418198](../images/041919/041919-4/0418198.gif)
![0418199](../images/041919/041919-4/0418199.gif)
![04181910](../images/041919/041919-4/04181910.gif)
![04181911](../images/041919/041919-4/04181911.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|